<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808403</url>
  </required_header>
  <id_info>
    <org_study_id>20140409</org_study_id>
    <nct_id>NCT02808403</nct_id>
  </id_info>
  <brief_title>Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan</brief_title>
  <official_title>Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab (AMG 145) in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing survey is to obtain real-world information on the safety
      and effectiveness of evolocumab in Japan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of study are to 1) determine the incidence of adverse events and adverse drug
      reactions among patients receiving evolocumab for up to 2 years, and 2) identify and
      describe patient characteristics (e.g. demographics, medical history) associated with the
      safety and effectiveness of evolocumab therapy for the patients with Familial
      Hypercholesterolemia (Heterozygous or Homozygous) and Hypercholesterolemia in Japan
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and adverse drug reactions</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence of adverse events and drug reactions will be described using the same units (events per 1000 person-years). Adverse events (including seriousness and causal relations to drug or device), inclusive of reaction at local injection sites, and other safety information (e.g. overdose, lack of effectiveness, pregnancy and lactation with or without adverse event) will be described.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for LDL-C</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for HDL-C</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for total cholesterol</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for triglycerides</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for Apolipoprotein (Apo) A1</measure>
    <time_frame>2 years</time_frame>
    <description>This will be measured if feasible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for Apolipoprotein (Apo) Apo B</measure>
    <time_frame>2 years</time_frame>
    <description>This will be measured if feasible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for Apolipoprotein (Apo) Apo E</measure>
    <time_frame>2 years</time_frame>
    <description>This will be measured if feasible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values for lipoprotein(a)</measure>
    <time_frame>2 years</time_frame>
    <description>This will be measured if feasible.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Evolocumab exposed</arm_group_label>
    <description>Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention; observation of routine medical care</description>
    <arm_group_label>Evolocumab exposed</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients for whom evolocumab is prescribed at participating medical institutions in
        accordance with the approved Japan prescribing information (i.e., those with Familial
        Hypercholesterolemia and Hypercholesterolemia who have high risk factors for
        cardiovascular event and do not respond sufficiently to Hydroxymethylglutaryl coenzyme A
        (HMG-CoA) reductase inhibitor (statin) for hypercholesterolemia.)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for whom evolocumab is prescribed at participating medical institutions in
             accordance with the approved Japan prescribing information (i.e., those with Familial
             Hypercholesterolemia (Heterozygous or Homozygous and Hypercholesterolemia who have
             high risk factors for cardiovascular event and do not respond sufficiently to HMGCoA
             reductase inhibitor (statin) for hypercholesterolemia).

        Exclusion Criteria:

          -  No exclusion criteria are applied.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma prefecture</state>
        <zip>370-3513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uchinada</city>
        <state>Ishikawa prefecture</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>June 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
